Skip To Main Content

Burden of Disease

RSV Is a Common Respiratory Virus With Symptoms Varying by Age-Group

Abbreviations

References

RSV Causes Substantial Disease Burden for Newborns and Infants Globally

Based on 2019 global data.

Reference

RSV Disease in Infants - GG - V1

RSV Disease in Infants - GG - V1

RSV is a Leading Cause of LRTIs Among Infants Worldwide1,2

Estimated Percentage of acute LRTI attributable to RSV infection

LRTI, lower respiratory tract infection.
Data are derived from different studies and over different years.

a Only includes hospitalizations due to bronchiolitis; bRSV was a cause of 28% of all hospitalization cases in infants in France. 

References

Prevalence in RSV hospitalized with bronchiolitis during seasonal epidemics

 aCoronavirus type OC43, 229E, NL63, and HKU1. Age range of children not specified.

References

RSV Average Hospitalization days

5.9 days   in hospital

6.5 days   in hospital

total of 754 beds (502 inpatient beds, 56 emergency beds, 77 ICU beds, 32 psychiatry beds, and 87 special auxiliary beds).

AComorbidities assessed: congenital cardiopathies, 2.3%; congenital defects with cardiac affectation, 0.7%; prematurity, 0.3%; bronchopulmonary dysplasia, 1%.

References

RSV Causes Substantial Hospitalization Among All Infants and Young Children In Spain

Epidemiologic survey in Spain estimating the burden of RSV in all children <5 years of age during a 15-year period (1997–2011)1


326,175
hospital discharges

 

Due to bronchiolitis in children <5 years of age


5.9 days
in hospital

 

on average in children ≤2 years of age


4,136/100,000 incidence of hospitalization during 1st year of life

 

highest incidence among all age ranges


446
deaths

 

355 (80%) <12 months of age 335 (75%) without comorbidities*


96.8 % of children were otherwise healthy

 

Only 3.2% of children <5 years of age presented with ≥1 comorbidity*

AComorbidities assessed: congenital cardiopathies, 2.3%; congenital defects with cardiac affectation, 0.7%; prematurity, 0.3%; bronchopulmonary dysplasia, 1%.

Reference

MAT-BH-2300309-V1-April-2023